Presenter William J. Sandborn, MD Professor of Medicine Chief, Division of Gastroenterology Director, UCSD IBD Center University of California San Diego UC San Diego Health System La Jolla, CA Additional Content Development Faculty Stephen B. Hanauer, MD Clifford Joseph Barborka Professor of Medicine Division of Gastroenterology and Hepatology Northwestern University Feinberg School of Medicine Chicago, IL
Adam S. Cheifetz, MD
Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard Medical School Boston, MA
Lawrence J. Brandt, MD
(CCME reviewer) Professor, Department of Medicine (Gastroenterology & Liver Diseases) Albert Einstein College of Medicine Bronx, NY
AMA PRA Category 1 Credit™ Medium
Treatment strategies for IBD vary depending on disease type, severity, and patient risk profile. This activity will examine severity and risk assessment, guideline recommended treatment, and patient communication strategies.
This activity is jointly provided by Albert Einstein College of Medicine and Montefiore Medical Center, and MCM Education.
Gastroenterologists and other clinicians involved in the management of patients with IBD including nurse practitioners (NPs), physician assistants (PAs), and nurses.
Upon completion of this educational activity, the participant should be able to:
Review the approaches to risk and severity assessment for patients with IBD, as it relates to treatment decision-making.
Discuss the treatment strategies for the management of patients with high-risk IBD, including the benefits and safety profile of biologic therapy.
Discuss the guideline recommendations and quality measures related to preventative care and screening needs in patients with IBD.
Describe practical approaches to patient engagement to optimize shared treatment decision-making.
The “Conflict of Interest Disclosure Policies” of Albert Einstein College of Medicine require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.
The Albert Einstein College of Medicine also require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.
Contributors whose COIs are irresolvable are not permitted to participate in Einstein CME activities.
William J. Sandborn, MD
Consultant: Janssen, AbbVie, UCB Pharma, Takeda, Pfizer, Genentech, Amgen, Medimmune, Celgene
Speakers Bureau: Janssen
Contracted Research: Janssen, AbbVie, Takeda, Pfizer, Genentech, Amgen, Celgene
Stephen B. Hanauer, MD
Consultant: AbbVie, Amgen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Genentech, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Prometheus, Receptos, Salix, Seres Health, Shire, Takeda, Tigenex, UCB
Speakers Bureau: AbbVie, Janssen, Takeda
Contracted Research: AbbVie, Amgen, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer, Prometheus, Receptos, Takeda, UCB
Adam S. Cheifetz, MD
Consultant: Janssen, Pfizer, Samsung
Lawrence J. Brandt, MD (CCME reviewer)
Nothing to disclose.
The staff of CCME of Albert Einstein College of Medicine have no disclosures to report with any commercial interests relative to this CME activity.
ACCME ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint providership of Albert Einstein College of Medicine, Montefiore Medical Center, and MCM Education. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
ACCME CREDIT DESIGNATION STATEMENT: Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support Statements
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Presented by Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, and MCM Education.
The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, or Takeda Pharmaceuticals U.S.A., Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.